Reportstack has announced a new market research report on the Global Acute Myeloid Leukemia Therapeutics Market 2015-2019. The expected entry of novel drugs to treat acute myeloid leukemia is one major trend upcoming in this market. It is expected to be the preferred treatment option among the medical fraternity, patients, and families of patients. This is expected to increase the number of treatment-seeking patients, which is expected to result in an increase in the overall consumption of medicines. The Global Acute Myeloid Leukemia Therapeutics market is expected to grow at a CAGR of 19.75 percent during the period 2014-2019.
The diagnosis of acute myeloid leukemia depends on the laboratory tests that detect anemia, thrombocytopenia, leucopenia, and leukocytosis, caused by the disturbances in hematopoietic function owing to bone marrow and peripheral blood infiltration. Differential diagnosis includes myelodysplastic syndromes, acute lymphoblastic leukemia, acute biphenotypic leukemia, chronic myeloid leukemia, and metastasis of rhabdomysarcoma and neuroblastoma.
“Vendors are increasingly forming alliances and undergoing M&A to increase their R&D activities aimed at developing novel drugs for the treatment of acute myeloid leukemia,”.
“Co-development agreements between different companies enable the utilization of technical expertise from both the companies for mutual benefits, allow the use of regulatory and developmental experience gained by one company to support the pipeline candidates of the other, and ensure the in-flow of adequate funds for R&D activities.”
To define the market conditions in the next 3-4 years, the analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
Complete report with TOC available @ Global Acute Myeloid Leukemia Therapeutics Market 2015-2019.